Synopsis: The shares of companies led by Shark Tank India judges remained in focus as investors assessed their Q4 FY26 performance, with businesses reporting varying levels of revenue growth, profitability, and operational expansion.
Three companies associated with Shark Tank India judges are listed on the stock exchanges operating across sectors such as eyewear, pharmaceuticals, and consumer products. These businesses range from new-age consumer brands to well-established companies with a strong market presence.
The Q4 FY26 results of companies linked to judges such as Peyush Bansal, Namita Thapar, and Ghazal Alagh provide insights into their revenue growth, profitability, and overall operational performance during the quarter.
Lenskart Solutions Ltd
Lenskart Solutions Ltd is one of India’s largest eyewear retailers, offering prescription glasses, sunglasses, contact lenses, and eye-care products. The company operates through an omnichannel model, combining a strong online platform with an extensive network of retail stores across India and international markets.
QoQ View: The revenue from operations grew by 9.0 percent to Rs 2,516 crore in Q4 FY26 from Rs 2,308 crore in Q3 FY26, and EBIDT grew by 16.0 percent to Rs 536 crore in Q4 FY26 from Rs 462 crore in Q3 FY26. This sequential growth was accompanied by a net profit expansion of 53.4 percent to Rs 204 crore in Q4 FY26 from Rs 133 crore in Q3 FY26, resulting in an EPS growth of 51.3 percent to Rs 1.15 per share from Rs 0.76 per share in Q3 FY26.
YoY View: The revenue from operations grew by 46 percent to Rs 2,516 crore in Q4 FY26 from Rs 1,728 crore in Q4 FY25, and EBIDT grew by 84 percent to Rs 536 crore in Q4 FY26 from Rs 292 crore in Q4 FY25. This was accompanied by an 8 percent decrease in net profit to Rs 204 crore in Q4 FY26 from Rs 220 crore in Q4 FY25, resulting in a 60 percent decrease in EPS to Rs 1.15 per share in Q4 FY26 from Rs 2.84 per share in Q4 FY25.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company engaged in developing, manufacturing, and marketing a wide range of medicines. The company has a strong presence across therapeutic segments, including gynecology, cardiology, HIV antivirals, and oncology, with operations spanning domestic and international markets.
QoQ View: The revenue from operations grew by 4.5 percent to Rs 2,470 crore in Q4 FY26 from Rs 2,363 crore in Q3 FY26, while EBIDT decreased by 2.6 percent to Rs 480 crore in Q4 FY26 from Rs 493 crore in Q3 FY26. This sequential performance was accompanied by a net profit growth of 5.6 percent to Rs 244 crore in Q4 FY26 from Rs 231 crore in Q3 FY26, resulting in a sequential EPS growth of 5.6 percent to Rs 12.84 per share from Rs 12.16 per share in Q3 FY26.
YoY View: The revenue from operations grew by 17 percent to Rs 2,470 crore in Q4 FY26 from Rs 2,116 crore in Q4 FY25, and EBIDT grew by 19 percent to Rs 480 crore in Q4 FY26 from Rs 402 crore in Q4 FY25. This was accompanied by a net profit growth of 23.84 percent to Rs 244 crore in Q4 FY26 from Rs 197 crore in Q4 FY25, resulting in an EPS growth of 29 percent to Rs 12.84 per share in Q4 FY26 from Rs 9.97 per share in Q4 FY25.
Honasa Consumer Ltd
Honasa Consumer Ltd is a digital-first consumer products company known for brands such as Mamaearth, The Derma Co., Aqualogica, and BBlunt. The company operates in the beauty, personal care, and wellness segments, leveraging online channels and an expanding offline distribution network to reach consumers across India.
QoQ View: The revenue from operations grew by 9.1 percent to Rs 657 crore in Q4 FY26 from Rs 602 crore in Q3 FY26, and EBIDT increased by 17.7 percent to Rs 77.1 crore in Q4 FY26 from Rs 65.5 crore in Q3 FY26. Sequentially, the operational expansion was accompanied by a net profit growth of 38.2 percent to Rs 69.4 crore in Q4 FY26 from Rs 50.2 crore in Q3 FY26, resulting in a sequential EPS growth of 38.3 percent to Rs 2.13 per share from Rs 1.54 per share in Q3 FY26.
YoY View: The revenue from operations grew by 23 percent to Rs 657 crore in Q4 FY26 from Rs 534 crore in Q4 FY25, and EBIDT grew by 186 percent to Rs 77.1 crore in Q4 FY26 from Rs 27.0 crore in Q4 FY25. This was accompanied by a net profit growth of 177 percent to Rs 69.4 crore in Q4 FY26 from Rs 25.0 crore in Q4 FY25, resulting in an EPS growth of 177 percent to Rs 2.13 per share in Q4 FY26 from Rs 0.77 per share in Q4 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
